Review concluded regarding general reimbursement for Bydureon

The Danish Medicines Agency has completed its review of an application for general reimbursement for Bydureon®. The product has been granted general reimbursement.

Bydureon® is used for the treatment of type 2 diabetes in adults.

When we compare Bydureon® with other similar medicines, we assess that the price of the medicine is commensurate with its therapeutic value.

The reimbursement status of Bydureon® will be reassessed in connection with the regular reassessment of the reimbursement status of all medicines.

Please find the Reimbursement Committee recommendation and the Danish Medicines Agency's decision in the box to the right (in Danish only).